Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Dec 20, 2011 9:36pm
267 Views
Post# 19340341

RE: 4Q Outlook....Transitioning.......

RE: 4Q Outlook....Transitioning.......Kwel2:

RE:"unconfirmed second hand reports, aka "exit interviews", suggest that the replacement of some personnel with "hands on" (nuggety ore) experience is well underway. Recall CMD (Exall's) operator/contractor was very familiar with this challenge."

[S] I've always cautioned that a switch in the management does not provide and continuity of ore production. You have to expect some transitioning as the learning curve get pushed back.

https://www.romios.com/i/Maps/TimminsZoom.gif

Hence the mention of the revisit to the (past producer) Gibson as ways to reduce the reliance on the UG until the deposit can be thoroughly understood. In nuggety ore the challange is a real one. Of course the bashers have a field day as they don't comprehend the difficulties being experienced. Recall: bulk sampling the C147. LOL. Lots going on, but it will take patience.

BWDIK? WD is to be commended for providing an early warning after the market close. The revised targets for 2012 suggests that the stope definition drilling and interpretation will take time. Definately not a stock for the impatient.

GLTAL-GLAP

Cheers
Stanley
Bullboard Posts